ProShares Ultra Nasdaq Biotechnology (BIB)

NASDAQ: BIB · IEX Real-Time Price · USD
62.28
+1.66 (2.74%)
At close: Feb 27, 2024, 3:59 PM
63.72
+1.44 (2.31%)
After-hours: Feb 27, 2024, 7:58 PM EST
2.74%
Assets $86.87M
Expense Ratio 0.95%
PE Ratio n/a
Shares Out 1.68M
Dividend (ttm) $0.04
Dividend Yield 0.06%
Ex-Dividend Date Dec 20, 2023
Payout Ratio n/a
1-Year Return +16.15%
Volume 39,925
Open 61.00
Previous Close 60.62
Day's Range 60.52 - 62.45
52-Week Low 40.10
52-Week High 62.45
Beta 1.54
Holdings 231
Inception Date Apr 8, 2010

About BIB

Fund Home Page

The ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index. The fund provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ. BIB was launched on Apr 8, 2010 and is issued by ProShares.

Asset Class Equity
Category Trading--Leveraged Equity
Stock Exchange NASDAQ
Ticker Symbol BIB
ETF Provider ProShares
Index Tracked NASDAQ / Biotechnology

Top 10 Holdings

144.68% of assets
Name Symbol Weight
NASDAQ BIO INDEX SWAP BNP n/a 48.80%
NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG n/a 23.27%
NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE n/a 22.14%
NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA n/a 15.01%
Vertex Pharmaceuticals Incorporated VRTX 6.78%
Regeneron Pharmaceuticals, Inc. REGN 6.67%
Amgen Inc. AMGN 6.00%
NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONAL n/a 5.95%
Gilead Sciences, Inc. GILD 5.37%
NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA n/a 4.69%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Dec 20, 2023 $0.03839 Dec 28, 2023
Dec 22, 2022 $0.01985 Dec 30, 2022
Sep 21, 2010 $0.011 Sep 28, 2010
Full Dividend History

News

Top Performing Leveraged/Inverse ETFs: 08/07/2022

Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

1 year ago - ETF Trends

Cap-Weighting Crucial When Indexing Biotech

The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in develo...

Other symbols: BISIBBQ
2 years ago - ETF Trends

How to Invest in Biotech in 2022

It's been a hard year for a lot of the biotech industry, with many hedge funds ending the year with significant losses, but there have been a number of shining stars that are expected to continue to o...

2 years ago - ETF Trends

Could Biotech ETFs Get Another Boost From JNJ News?

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. Thi...

Other symbols: PBE
2 years ago - ETF Trends

Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval

The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that offic...

Other symbols: BNTXPFE
2 years ago - ETF Trends

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be...

Other symbols: PBE
2 years ago - ETF Trends

As Covid Cases Mutate, the Biotech Industry Works to Keep Up

As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt t...

2 years ago - ETF Trends